147 related articles for article (PubMed ID: 33634023)
1. Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma.
Ge J; Li C; Xue F; Qi S; Gao Z; Yu C; Zhang J
Front Oncol; 2020; 10():601175. PubMed ID: 33634023
[TBL] [Abstract][Full Text] [Related]
2. Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study.
Wang Y; Meng X; Zhou S; Zhu Y; Xu J; Tao R
Onco Targets Ther; 2019; 12():10579-10585. PubMed ID: 31819537
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
4. Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option.
Zhang HH; Du XJ; Deng ML; Zheng L; Yao DC; Wang ZQ; Yang QY; Wu SX
Front Pharmacol; 2022; 13():969565. PubMed ID: 36060005
[No Abstract] [Full Text] [Related]
5. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma.
Lin H; Zhou X; Sheng X; Liang X
Drugs R D; 2023 Sep; 23(3):239-244. PubMed ID: 37466833
[TBL] [Abstract][Full Text] [Related]
7. Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Zhu Y; Zhao L; Xu Y; Zhan W; Sun X; Xu X
Ann Palliat Med; 2022 Jan; 11(1):394-400. PubMed ID: 35144430
[TBL] [Abstract][Full Text] [Related]
8. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
9. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
11. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
12. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis.
Li G; Xu X; Cui J; Zhang F; Wang S
Exp Ther Med; 2023 Sep; 26(3):452. PubMed ID: 37614429
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM
Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
17. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
Lu G; Rao M; Zhu P; Liang B; El-Nazer RT; Fonkem E; Bhattacharjee MB; Zhu JJ
Front Neurol; 2019; 10():42. PubMed ID: 30766509
[TBL] [Abstract][Full Text] [Related]
18. Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.
Ge JJ; Li C; Qi SP; Xue FJ; Gao ZM; Yu CJ; Zhang JP
BMC Cancer; 2020 Jan; 20(1):24. PubMed ID: 31914946
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study.
Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y
Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866
[TBL] [Abstract][Full Text] [Related]
20. The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum-resistant ovarian cancer patients: A comparative cohort study.
Wu C; Yan J; Wu Y
J Obstet Gynaecol Res; 2024 Jun; ():. PubMed ID: 38839575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
